Amicus Therapeutics, Inc. (FOLD)
$14.49+0.00%Close
BUYBULL · day 98
Key stats
- Market cap
- $4.5B
- Beta
- 0.48
- P/E (TTM)
- -783.24
- 1W
- +0.21%
- 1M
- +0.42%
- vs SPY 1W
- -0.95%
- vs SPY 1M
- -2.58%
Industry peers
FMP comparable companies · ranked by market cap
- KNSABUYKiniksa Pharmaceuticals International, plc$5.8BBULLQ 24$76.31+1.31%
- CDTXCidara Therapeutics, Inc.$5.6B$221.38
- SRRKSELLScholar Rock Holding Corporation$5.2BCRISISQ 22$43.40-0.02%
- ADPTBUYAdaptive Biotechnologies Corporation$4.8BCRISISQ 6$29.84+1.53%
- CPRXBUYCatalyst Pharmaceuticals, Inc.$3.9BBULLQ 20$31.49+0.00%
- IDYASELLIDEAYA Biosciences, Inc.$3.6BBEARQ 25$38.06+0.14%
- LEGNSELLLegend Biotech Corporation$3.5BRECOVERYQ 2$18.77-0.48%
- TARSSELLTarsus Pharmaceuticals, Inc.$3.2BBEARQ 24$74.45+1.30%
- ARQTSELLArcutis Biotherapeutics, Inc.$3.1BRECOVERYQ 11$25.15+8.53%
- MLYSSELLMineralys Therapeutics, Inc.$2.1BCRISISQ 19$23.30+4.42%
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
Company news
FAQ
- What is LOPJLB’s current signal on FOLD?
- LOPJLB’s latest quantitative signal on Amicus Therapeutics, Inc. (FOLD) is BUY in a BULL regime. Signals are updated daily.
- What market regime is FOLD in?
- Amicus Therapeutics, Inc. (FOLD) is currently classified in the BULL HMM market regime on LOPJLB.
- What does Amicus Therapeutics, Inc. (FOLD) do?
- Amicus Therapeutics, Inc. is a biotechnology firm dedicated to the discovery, development, and delivery of medical treatments for rare conditions. Its primary commercial offering is Galafold, an orally administered precision medicine designed for adult patients with a confirmed diagnosis of Fabry disease, specifically those exhibiting an amenable galactosidase alpha gene variant as identified b…